INTRODUCTION
Breast cancer is the most common cancer among women worldwide. 1 Although it has yet to be determined what initially causes the onset of breast cancer, research suggests potential links to dietary habits and fat intake. 2 The contribution to mammary carcinogenesis of dietary omega-3 (n-3) polyunsaturated fatty acids (PUFAs) and omega-6 (n-6) PUFAs has received considerable attention in the literature, 3, 4 with some epidemiological studies suggesting a preventative effect of n-3 PUFAs, and a promoting effect of n-6 PUFAs, on breast cancer. Other studies, however, have failed to demonstrate a statistically significant association between n-3 PUFAs and reduced breast cancer risk. 4, 5 Although increasing evidence from preclinical (animal and in vitro) studies indicates that n-3 PUFAs present in fatty fish and fish oils inhibit breast carcinogenesis, inconsistencies remain. [6] [7] [8] [9] Several confounding factors may account for the inconsistent results, namely: (1) wide variations in the amount and source of n-3 PUFAs consumed in each study; (2) the ratio of n-6 to -3 may be more important than the absolute amount of n-3 PUFA, as suggested by animal and human studies; (3) results will depend upon the type and even the bioavailability (triglyceride or ester) of n-3 PUFAs used in the studies; and (4) the length of time of the n-3 PUFA diet will also affect the outcome of any study. 6 Collectively, these inconsistencies preclude definitive conclusions, or in-depth mechanistic investigations, in this area. Consequently, no recommendations can be offered to women regarding n-3 PUFA ingestion for reduction of breast cancer risk, and, to date, a unifying mechanistic hypothesis addressing how n-3 PUFAs suppress breast cancer compared with n-6 PUFAs is lacking.
Mammalian target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that integrates diverse signals including nutrients, growth factors, energy and stresses to control cell growth, proliferation, survival and metabolism. [10] [11] [12] [13] mTOR elicits its pleiotropic functions in the context of two functionally distinct signaling complexes, termed mTOR complex 1 (mTORC1) and complex 2 (mTORC2). mTORC1, which contains mTOR, mLST8/ GbL, Raptor and PRAS40, plays a key role in translation initiation by directly phosphorylating p70 S6 kinase 1 (S6K1) and 4E-BP1, and is sensitive to rapamycin. mTORC2 shares mTOR and mLST8/ GbL with mTORC1, but possesses three unique components, namely, rictor, mSin1 and PRR5/Protor. Despite the presence of mTOR, mTORC2 is not susceptible to acute rapamycin inhibition. The function of mTORC2 is less clear, but it has been shown to phosphorylate Akt at serine 473 and to regulate cytoskeleton organization and cell motility. 12, 13 As a major cancer drug target, mTORC1/2 signaling is upregulated in most of the cancers and plays critical roles in carcinogenesis and in the progression of cancers.
14 That said, the extra-and intracellular dietary stimuli, and the deregulated metabolic reactions that cause upregulation of mTOR signaling in cancer cells, are unclear. Our recent work identified a critical role for the n-6 PUFA arachidonic acid (AA) in the activation of mTORC1/2 signaling in breast carcinogenesis and angiogenesis. 15 The effect of n-3 PUFAs on mTORC1/2 signaling and the mechanisms through which n-3 PUFAs regulate mTORC1/ 2 are, however, unknown.
We have previously developed a transgenic mouse model that expresses a gene, fat-1, encoding an n-3 fatty acid desaturase. 16 As this enzyme can catalyze the conversion of n-6 PUFA to n-3 PUFA by introducing a double bond into fatty acyl chains, transgenic expression of fat-1 enables the host to produce n-3 PUFAs endogenously while concomitantly reducing the levels of n-6 PUFAs. fat-1 transgenic mice will also enable the investigation of the biological properties of n-3 PUFAs without having to incorporate n-3 PUFAs such as docosahexaenoic acid (DHA) in the diet. 17 To identify the preventive effects of n-3 PUFAs against breast tumor development as well as to investigate the underlying mechanisms, we developed fat-1 transgenic severe combined immune deficiency (SCID) mice and fat-1 transgenic mouse mammary tumor virus (MMTV, an aggressive breast cancer model) double-hybrid mice. Using these genetic models, combined with a conventional dietary approach, our results unequivocally demonstrate that n-3 PUFAs target both mTORC1 and mTORC2 pathways and efficiently inhibit mammary tumorigenesis and progression.
RESULTS
Dietary n-3 PUFAs prevent N-methyl-N-nitrosourea (MNU)-induced rat mammary tumorigenesis and inhibit mTORC1/2 signaling in vivo n-3 PUFAs have been shown to antagonize the effect of n-6 PUFAs on cancer development through undefined mechanisms. 18, 19 We have previously shown that n-6 PUFA AA-activated mTORC1 and mTORC2 signaling are critical for its stimulatory role in breast carcinogenesis and angiogenesis. 15 In this study, we found that dietary n-3 PUFAs efficiently reduced the incidence of MNUinduced mammary tumors: 62.5% for low n-3/n-6 PUFAs diet versus 30% for high n-3/n-6 PUFAs diet (Figure 1a and  Supplementary Table S1 ). Average mammary tumor weights (1.68 ± 0.69 versus 0.22 ± 0.08 g, P ¼ 0.09) and the number of tumors per mouse were also remarkably reduced in rats treated with high n-3/n-6 PUFAs (Figure 1a) . Interestingly, high dietary n-3 PUFAs repressed both mTORC1 and mTORC2 signaling pathways in vivo, as manifest by decreased phosphorylation levels of S6K1 (T389), S6 (S235/236 and S240/244), 4E-BP1, Akt (S473) and ERK (T202/Y204) in rats with high n-3/n-6 PUFA diet (Figures 1b and c) . We suggest that the decrease of mTORC1/2 signaling by n-3 PUFAs may play a role in their inhibitory effects on mammary carcinogenesis and progression. n-3 PUFAs inhibit mTOR1/2 signaling in breast cancer cell lines To investigate the underlying mechanisms of the effect of n-3 PUFAs on mTORC1/2 signaling in vitro, we first examined whether n-3 PUFA DHA inhibits mTORC1/2 in breast cancer cell lines. In MCF-7 cells, DHA rapidly and dose-dependently suppressed insulin-, AA-and amino acids-stimulated mTORC1-directed phosphorylation of S6K1 (T389), S6 (S235/235) and 4E-BP1 and mTORC2-directed phosphorylation of Akt (S473) and its downstream target GSK-3b (S9) (Figures 2a-d) . Similarly, DHA treatment inhibited insulin-, AA-and amino acid-induced mTORC1 and mTORC2 activation in other breast cancer cell lines, including MDA-MB-231 and T47D (Supplementary Figures S1a-c) . We next examined the role of endogenously produced n-3 PUFAs in mTORC1/2 signaling. In MCF-7 cells transfected with the fat-1 cDNA, the phosphorylation of S6K1 (T389), S6 (S235/235), 4EBP1, Akt (S473) and GSK-3b (S9) was significantly reduced compared with cells transfected with the control vector (Figure 2e ). These results suggest that both mTORC1 and mTORC2 signaling pathways are targets of exogenous and endogenous n-3 PUFAs in breast cancer cells.
AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 1/2 (TSC1/2) are upstream signals that negatively regulate mTORC1. 20, 21 It has been well established that mitogens such as insulin and growth factors activate mTORC1 via a PI3-K/ Akt/TSC2-dependent pathway. 12, 13 DHA has been shown to reduce insulin-like growth factor 1 receptor (IGF1R)/PI3-K/Akt activity and stimulate AMPK in vivo or in vitro. 22, 23 To understand the mechanism through which n-3 PUFA inhibits mTORC1, the roles of AMPK/TSC in this process were examined. DHA increased phosphorylation of AMPK (T172) in a dose-dependent manner in MCF-7 cells (Supplementary Figure S2a) . AMPK siRNA effectively downregulated levels of AMPK, and slightly prevented DHAinduced dephosphorylation of S6K (T389) and S6 (S235/236, S240/ 244) ( Figure 3a, Supplementary Figure S2b) . Moreover, although Compound C, an AMPK-specific inhibitor, significantly counteracted the elevation of phospho-AMPK (T172) by DHA (Supplementary Figure S2c) , it was unable to completely block the inhibitory effects of DHA on mTORC1, and only slightly rescued the mTORC1 activity repressed by DHA (Figure 3b) . Similarly, knockdown of TSC2 by siRNA could not rescue DHA-induced decrease of p-S6K (T389) and p-S6 (S235/236, S240/244) ( Figure 3c ) and this result was also observed in TSC2 À / À mouse embryo fibroblasts (Figure 3d and Supplementary Figure S2d) . These data indicate that activation of AMPK/TSC2 is not required for rapid inhibition of mTORC1 by DHA. Notably, DHA inhibited insulin-and AA-stimulated mTORC1/2 signaling, but failed to repress PI3-K/ phosphoinositide-dependent protein kinase-1 (PDK1)-directed phosphorylation of Akt (T308) within 30 min (Figures 2a-d) . These data suggest that alternative mechanisms may be involved in the rapid inhibition of mTORC1/2 by DHA. This notion was evidenced by the fact that DHA did not repress PI3K-directed phophorylation of PDK1 (S241) (Supplementary Figure S2e) , and that constitutively active Akt (Akt-CA) could not block the inhibitory effects of DHA on mTORC1 (Supplementary Figure S2f) . This notion was further confirmed by our finding that amino acids-stimulated mTORC1 activity, which has been well established to activate mTORC1 through a PI3-K/TSC2-independent mechanism, was also rapidly blocked by DHA (Figures 2c and  d) . Moreover, we previously showed that AA activates mTORC1/2 in the absence of amino acids and serum via a TSC-independent mechanism. DHA also blocked AA-stimulated mTORC1/2 activity in cells that had undergone serum and amino-acid starvation (Figures 2b and d) .
The assembly and stability of mTOR complexes contribute to their kinase activity 24 and two studies have suggested that a redox-sensitive mechanism may contribute to the regulation of Raptor-mTOR interaction and mTORC1 activity. 25, 26 The reducing reagent 2, 3-dimercapto-1-propanol has been shown to stabilize the interaction of mTOR and Raptor and to inhibit mTORC1 activity. 25 We next asked whether DHA acts as an antioxidant and regulates the stability of mTOR complexes. Interestingly, DHA stabilized the mTOR-Raptor interaction (Figure 3e ), and inhibited mTORC1 activity, as manifested by reduced mTORC1 in vitro kinase activity by DHA under either presence or absence of amino acids (Figure 3f ), indicating that stabilization of the mTOR-Raptor complex by DHA may be important for its inhibitory effects against mTORC1. The stability of mTORC2 (mainly mTOR-rictor interaction) was found to be insusceptible to DHA; however, a decreased mTORC2 in vitro kinase activity was observed n-3 PUFAs target mTORC1/2 and inhibit breast cancer Z Chen et al ( Figure 3g ). This result was similar to what has been revealed in our previous report, that mTORC2 kinase activity was stimulated by AA, although the stability of mTORC2 remained unchanged. These results indicated distinct mechanisms involved in the inhibitory effects of DHA on mTORC1 and mTORC2.
Effects of n-3 PUFAs on mTORC1/2 signaling downstream targets Cyclin D1, hypoxia-induced factor 1 a and vascular endothelial growth factor (VEGF) are three key mTORC1 downstream signaling molecules whose expression is positively regulated by mTORC1 and that are responsible for mTORC1-related pathogenesis and progression of cancer. [27] [28] [29] To further confirm the inhibitory role of n-3 PUFAs on mTORC1 signaling, we examined the effect of DHA on cyclin D1, HIF-a and VEGF protein levels in MCF-7 cells. Cobalt chloride (CoCl 2 ) is a commonly used hypoxia-mimetic agent; like hypoxia, it can block the degradation and thus induce the accumulation of hypoxia-induced factor 1 a protein. As expected, DHA reduced CoCl 2 -induced hypoxia-induced factor 1 a and cyclin D1 expression levels in MCF-7 and MDA-MB-231 cells (Figures 4a-d) . Secretion of VEGF-a in their culture supertanant was also significantly reduced by DHA treatment (Figures 4e and f) . Moreover, expression of fat-1 decreased VEGF and HIF-1a levels in MCF-7 cells (Supplementary Figure S3) . Consistent with these results, inhibition of mTORC1 by DHA or fat-1 led to suppression of MCF-7 and MDA-MB-231 cell proliferation (Supplementary Figure S4) and angiogenesis in a chick chorioallantoic membrane angiogenesis assay (Supplementary Figure S5) . Akt has been identified as a substrate of mTORC2 in the promotion of cell survival. Similarly, inhibition of mTORC2/Akt (S473) by DHA and fat-1 promoted breast cancer cell apoptosis (Supplementary Figure S6) . Taken together, these results further confirmed that both mTORC1 and mTORC2 pathways are targets of n-3 PUFAs and are involved in the suppression of breast cancer cell proliferation, survival, angiogenesis and in the potentiation of breast cancer cell apoptosis.
Endogenously produced n-3 PUFAs inhibit mTORC1/2 signaling and prevent breast tumor growth in xenograft models To further identify the role of n-3 PUFAs in mTORC1/2 signaling and breast tumor growth in vivo, we established two breast tumor xenograft models producing endogenous n-3 PUFAs. Firstly, breast cancer MDA-MB-231 cells stably expressing fat-1, or control vector, were subcutaneously implanted into nude mice (Supplementary Figure S7) . Data in Figure 5 and Supplementary Figure S7 show that fat-1 gene expression significantly diminished tumor volume and tumor weight compared with its control. Importantly, phosphorylation of S6K1 (T389), S6 (S235/236) and Akt (S473) was reduced in tumors with fat-1 gene expression compared with its control (Figure 5c ). These results demonstrate that cellular production of n-3 PUFAs and a reduced n-6/n-3 ratio in breast cancer cells inhibit mTORC1/2 signaling and prevent their growth in vivo. In addition, levels of VEGF and HIF-1a were reduced, while cleavage of poly (ADP-ribose) polymerase (PARP) was enhanced, in fat-1 expression tumors (Supplementary Figure S7) .
Next, we established fat-1 transgenic SCID mice (Supplementary Figure S8a) . Fatty acid composition analysis identified a significantly increased ratio of n-3/n-6 PUFAs in these mice compared with control SCID mice lacking fat-1 expression (Supplementary  Table S4 ). Interestingly, although xenograft tumors with an average volume of 3 cm 3 were observed within 3 weeks in control SCID mice, we failed to observe tumor growth in any of the fat-1 SCID animals (Figures 5d and e and Supplementary Figure S8b) . Moreover, levels of phosphorylated S6K1 (T389), S6 
(S235/236) and Akt (S473) were lower in the livers of fat-1 SCID mice compared with control mice (Figure 5f ). We suggest that mTORC1 and mTORC2 signaling are targets of n-3 PUFAs in vivo, and that breast tumor cells are unable to proliferate or survive in the presence of high levels of endogenously produced n-3 PUFAs in vivo. Taken together, these data unequivocally demonstrate that endogenously produced n-3 PUFAs target mTORC1/2 pathways and prevent breast tumor growth in vivo.
Reduced mTORC1/2 activities and suppression of mammary tumorigenesis and progression in fat-1 transgenic MMTV-PyVT breast cancer mouse model We next asked whether an increased n-3/n-6 PUFA ratio arising from endogenous production of n-3 PUFAs prevents mammary tumorigenesis and metastasis. The fat-1 mouse was crossed with the MMTV-PyVT transgenic mouse, a model of highly aggressive breast cancer, to create a novel double-hybrid mouse that provides a purely genetic approach to investigate the effects of n-3 PUFA exposure on mammary tumorigenesis and development (Supplementary Figure S9a) . After euthanization, the number of tumors palpated in PyVT-fat-1 mice was significantly less (Po0.05) than the number palpated in PyVT control mice (Figure 6a and Supplementary Figure S9b) . Moreover, the volume of tumors in
PyVT-fat-1 mice was also much less than that in PyVT mice (Figures 6b and c) . Table S5 ). mTORC2 has been shown to regulate epithelial-mesenchymal transition, motility and metastasis of colorectal cancer and ovarian cancer cells. 29, 30 We observed the repression of mTORC2 in the presence of an increased n-3/n-6 PUFA ratio, and reduced breast cancer metastasis, as lung metastasis was observed in PyVT mice while no metastastic tumors were detectable in PyVT-fat-1 mice (Figures 6f-h ). These data clearly show that reduction of n-6 PUFAs and enrichment of n-3 PUFAs in mouse decrease mTORC1/2 activities, and thus may contribute to preventing breast carcinogenesis and metastasis.
DISCUSSION
Using breast cancer cell lines and four complementary animal models, this study provides convincing evidence that both 
and TSC2
À / À MEFs were serum-starved (S -) for 18 h and the subsequent treatments were the same as in (a). (e) MCF-7 cells were starved for amino acids with or without DHA for 30 min, followed by adding back amino acids (1 Â ) for another 30 min. Cells were lysed and mTOR was immunopurified. (f) HEK293 cells were deprived of amino acids in the presence or absence of 75 mM DHA for 30 min, then amino acids (1 Â ) were added back in the presence or absence of DHA for another 30 min. Cells were lysed and immunoprecipitated (IP) with mTOR antibody or rabbit IgG, and the IP products were subjected to mTORC1 kinase assay using GST-4EBP1 as a substrate. Kinase control indicates the same kinase assay system without IP products. The blots from three independent experiments were quantified and normalized to the Control (cells cultured in normal media with amino acids and 10% FBS), and the values were presented as mean ± s.e. (g) HEK293 cells were deprived of serum for 24 h, subsequently incubated with or without DHA for 30 min, and stimulated with insulin in the presence or absence of DHA for another 30 min. After stimulation, cells were lysed and immunoprecipitated (IP) with mTOR antibody or rabbit IgG, and the IP products were subjected to mTORC2 kinase assay using inactive Akt as a substrate. The blots from three independent experiments were quantified and normalized to the control (cells cultured in normal media with amino acids and 10% FBS), and the values were presented as mean±s.e. exogenous and endogenous n-3 PUFAs efficiently prevent breast carcinogenesis and tumor development through inhibition of cell proliferation, tumor angiogenesis and induction of apoptosis. First, in an MNU-induced rat breast tumor model, a high dietary ratio of n-3/n-6 PUFAs efficiently reduced the incidence, average tumor weights and multiplicity of mammary tumors. This result was consistent with the outcomes of previous studies 22, [31] [32] [33] and indicated dietary n-3 PUFAs can prevent chemically induced mammary tumorigenesis. Second, two breast tumor xenograft models producing endogenous n-3 PUFAs were established for the first time. The growth of implanted tumor cells either producing n-3 PUFAs themselves or taking up n-3 PUFAs from their environment was remarkably suppressed in these xenograft models. It is interesting that breast tumor cells did not grow at all in fat-1 transgenic SCID mice. It is possible that cells stably expressing fat-1 have adapted to the high level of intracellular n-3 PUFAs and could have a lower proliferation rate in nude mice. In fat-1 transgenic SCID mice, however, the transplanted cells would undergo growth inhibition and apoptosis after taking up high levels of n-3 PUFAs from the immediate environment. Third, novel fat-1 and MMTV-PyVT double-hybrid mice were used to investigate the effects of endogenous n-3 PUFA exposure on mammary tumorigenesis and metastasis. The inhibitory effects of n-3 PUFAs on tumor volume, weight and multiplicity in this study were much more evident than in a recent report in which fat-1 transgenic MMTV-neu (ndl)-YD5 was used. 34 Moreover, in the current study, we found that fat-1 expression also prevents breast tumor metastasis. It will be interesting in future studies to probe whether PyVT-driven tumors are more sensitive to n-3 PUFAs than HER-2-riven tumors. Finally, our in vitro study clearly showed that DHA and cellular production of n-3 PUFAs inhibits proliferation and angiogenesis, and promotes apoptosis, in breast cancer cell lines. Taken together, the models employed in this study are complementary, simplistic yet elegant platforms to study the impact of exposure to n-3 PUFAs on breast cancer. The use of mice or cells expressing the fat-1 gene provides well-controlled experimental conditions for studying the biological effects of n-3 PUFAs and a balanced n-3/n-6 PUFA ratio without the need for incorporation of DHA in the diet or medium, and is an important addition to current conventional methods. Taken together, our study provides reliable and meaningful evidence for the prevention of mammary tumorigenesis and development by n-3 PUFAs.
Understanding of the signaling pathways regulated by n-3 and n-6 PUFAs in cancer provides insights into its etiology, as well as valuable information for assessing their potential value in both cancer prevention and cancer treatment. We have recently demonstrated the critical role of the AA-activated mTOR signaling pathway in angiogenesis and tumorigenesis of breast cancer. 15 A recent study reported that dietary n-3 PUFAs reduced phosphorylation of mTOR, S6K1 and 4E-BP1 in MNU-induced rat mammary tumors, suggesting a potential inhibitory role for n-3 PUFAs in the mTORC1 pathway. 22 On the contrary, in bovine muscle, dietary n-3 PUFAs has been shown to promote both n-3 PUFAs target mTORC1/2 and inhibit breast cancer Z Chen et al insulin-stimulated Akt-mTOR-S6K1 and insulin sensitivity. 35 The current study clearly demonstrates that both exogenous and endogenous n-3 PUFAs strongly inhibit mTORC1/2 signaling and their downstream targets in breast cancer cell lines and a variety of animal models. Furthermore, the ability of n-3 PUFAs to block both mTORC1 and mTORC2 could explain why dietary DHA is more effective than the mTORC1 inhibitor rapamycin in the suppression of mammary tumorigenesis. 15 In addition, n-3 PUFAs have been shown to have multiple biological effects on cancers, including alterations in the properties of cancer cells (proliferation, invasion and apoptosis) as well as those of host cells (inflammation, immune response and angiogenesis). 36, 37 mTOR is a central regulator of these biological processes, and mTORC1/2 pathways are upregulated in most human cancers, as well as involved in the pathogenesis and progression of breast cancer. 38 Together, these studies support the hypothesis that mTORC1/2 pathways are targets of n-3 PUFAs in the prevention of mammary tumorigenesis and development.
Mitogens such as insulin and growth factors activate mTOR through IRS/PI3-K/Akt/TSC-dependent pathways. 12 Studies have shown that n-3 PUFAs may reduce protein levels of IGF1R and increase PTEN level in vivo, subsequently suppressing IRS/PI3-K/ Akt activities. 22, 39 While this pathway represents one mechanism through which n-3 PUFAs inhibit mTOR, our results indicate that alternative mechanisms are also involved. While transcriptional and translational regulation of IGF1R or PTEN protein levels by n-3 PUFAs would occur over a longer time (more than 4 h), DHA caused mTORC1/2 inhibition only after 8 h when cells were cultured in the medium containing 10% FBS (Supplementary Figure S10) . However, DHA rapidly (within 30 min) blocked insulinand AA-stimulated mTORC1/2 signaling in serum-starved cells. Furthermore, DHA inhibited amino-acid stimulation of mTORC1, which has been well established as a mechanism for activation of mTORC1 independent of PI3-K/TSC2. 11, 13 Most importantly, DHA failed to reduce PI3-K-directed phosphorylation of PDK1(S241) and of Akt (T308) within 30 min, suggesting that PI3-K is not required for its inhibitory effect on mTORC1. AMPK, a protein complex that responds to change in cellular AMP/ATP ratios, has been shown to inhibit mTORC1 through either TSC-dependent or -independent mechanisms. More recently, it has been shown that AMPK is n-3 PUFAs target mTORC1/2 and inhibit breast cancer Z Chen et al activated by DHA in cells harboring wild-type p53, 23 and this result was recapitulated in MCF-7 cells in this study. However, activation of AMPK/TSC2 is less important for rapid inhibition of mTORC1 by DHA, as AMPK or TSC2 inhibition could not block the negative effect of DHA on mTORC1 activity, but only slightly rescued the mTORC1 activity. In addition, overexpression of Rheb, a direct activator of mTORC1, cannot blunt the suppression of breast cell proliferation by DHA (Supplementary Figure S11) . Further evidence indicated that DHA may act as an antioxidant to stabilize the mTOR-Raptor complex and inhibit mTORC1 and mTORC2 kinase activity. Together, our results implicate that stabilization of the mTOR-raptor complex may play an important role in the inhibition of mTORC1 by DHA. While AMPK/TSC signaling has a low impact on this process, the involvement of other signaling pathways such as ERK, which is targeted by n-3 PUFAs and contributes to mTORC1 activity in a certain context, could not be excluded.
In conclusion, using a variety of breast tumor cell and animal models, we have shown that (a) both endogenously synthesized and exogenously uptaken n-3 PUFAs prevent mammary tumorigenesis and metastasis; (b) mTORC1/2 signaling pathways are potential targets of n-3 PUFAs in the inhibition of breast cancer; and (c) stabilization of the mTOR-Raptor complex by n-3 PUFAs may contribute to their rapid inhibition of mTOR. These findings Figure 6 . High ratio of n-3/n-6 PUFAs reduces mTORC1/2 activities and prevents mammary tumorigenesis and metastasis in MMTV-PyVT/fat-1 mice. (a) Female PyVT-fat-1 mice (n ¼ 9) and control female PyVT mice (n ¼ 11) from the same litter were killed for mammary tumorigenesis analysis. Numbers of mammary glands with grossly visible tumors were counted after exposing the abdominal inner skin. Bars indicate mean ± s.d. n-3 PUFAs target mTORC1/2 and inhibit breast cancer Z Chen et al convincingly clarify the casual relationship between n-3 PUFAs and breast cancer prevention.
MATERIALS AND METHODS

Rat mammary tumorigenesis assay
The rat mammary tumor model was created by administrating MNU to female rats as described previously. 15 Briefly, 8-week-old female SpragueDawley rats (150-200 g) were given a single intraperitoneal injection of 50 mg/kg MNU (Sigma Chemical, Shanghai, China). A week later, they were randomized into control and experimental groups (n ¼ 10), which were intragastrically administered a low, or high, n-3 PUFA diet (Supplementary  Table S1 ) every 24 h for 3 months. All animals were weighed and palpated for mammary lesions weekly. At the end of the experiment, rats were killed by cervical dislocation and tumors were excised, weighed and counted. Proteins from tumors of both groups were extracted for western blot analysis.
Cell culture 
Xenografts in athymic nude mice
Four-week-old female BALB/c nude mice were purchased from Guangdong Medical Experimental Animal Center (Guangzhou, China). The mice were randomized into two groups and injected via the flank with 100 ml (1 Â 10 6 ) of cell suspension of MDA-MB-231 stable cell lines as described above. A bidimensional tumor measurement was taken every other day. Tumor volume (mm 3 ) was measured along two major axes using a vernier caliper and was calculated as follows: V ¼ 4/3pR 1 2 R 2 , where R 1 oR 2 . At the end of the experiment, mice were killed and tumors were carefully removed, weighed, and minced and lysed for western blot analysis.
Xenografts in SCID (severe combined immune deficiency) and fat-1-SCID mice Homozygous SCID mice (Jax Number: 001131) were bred with fat-1 transgenic mice produced previously 16 to generate female fat-1-SCID double-hybrid mice; female littermates lacking the fat-1 transgenic gene were used as control. DNA extractions from the tail tips of offspring were subjected to PCR for genotyping in accordance with the protocol on the Jackson Laboratory webpage, using the primers listed in Supplementary  Table S2 . PCR products were subjected to enzymatic digestion by Alu/and finally determined by 5% agarose electrophoresis. Four-week-old female homozygous SCID mice with or without fat-1 gene were injected with 100 ml (1Â 10 5 ) of cell suspension of MDA-MB-231 cells. Subsequent bidimensional tumor measurement and tumor sample analysis were performed as described above.
MMTV-PyVT mammary tumor model MMTV-PyVT (polyoma virus middle T oncogene) mammary tumorigenesis model mice were obtained from the Jackson Laboratory (Stock Number: 002374). Male MMTV-PyVT mice were bred with female fat-1 mice to generate female PyVT-fat-1 double-hybrid mice, and female littermates lacking the fat-1 gene were used as controls. Genotypes were confirmed by PCR using the primers listed in Supplementary Table S2 . Animals were weighed and palpated for mammary lesions weekly. Mice aged 14-16 weeks were killed by cervical dislocation because of the high tumor burden on PyVT mice and it being an appropriate time for lung metastasis analysis (see Supplementary methods). All tumors were excised, weighed and counted for multiplicity analysis. Proteins from tumors of both groups were extracted for western blot analysis.
Statistical analysis
All animal experiments were approved by the Ethical Committee of Southern Medical University. Data are presented as mean±s.d. of at least three independent experiments. Differences between groups were analyzed using Student's t test (SPSS 13.0), and a level of Po0.05 was considered statistically significant. In the case of western blot analysis, one representative set of data is shown.
